| ID | 1368 |
| Name of the vaccine | PA83-FhCMB |
| Microbe | Bacteria |
| Disease name | Anthrax |
| Name of bacteria | Bacillus anthracis |
| Type of vaccine | Recombinant |
| Nucleic acid content | Linear DNA |
| Age | 18 to 49 years |
| Description of the vaccine | Plant-derived recombinant protective antigen (rPA) Anthrax vaccine. |
| Name of the manufacturer | Fraunhofer, Centre for Molecular Biotechnology |
| Name of the manufacturing country | United States |
| Year of manufacture | 2015 |
| Clinical Phase status | Clinical - Phase 1 |
| Bacterial strain | Gram-positive, rod-shaped bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Four dose levels with Alhydrogel. |
| Mechanism of action | NA |
| Route of administration | NA |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | Alhydrogel |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | Yes (Zoonotic disease through contact with an infected animal or by inhaling spores) |
| PubMed identifier | NA |
| Clinical trial number | NCT02239172 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|